A single cell that has the ability to rapidly clone itself and grow into a full colony
Exploiting the phenotypic states of cancer to identify new avenues of diagnosis and treatment
ABOUT US
SINGLECELL BIOTECHNOLOGY
-
Launched in February of 2022
-
Licensed technology from The UT Southwestern Medical Center
-
Located in the heart of North Texas Bio Community at Pegasus Park, Dallas
OUR TEAM
-
Bryan Presley - President
-
Digant Dave', PhD - Science Advisor
-
Robert Bachoo, MD, PhD - Science Advisor
-
Elizibeth Maher, MD, PhD - Science Advisor
-
Azam Anwar, MD - Chairman
TECHNOLOGY
SingleCell Biotechnology has developed a new platform of assays to target highly aggressive and invasive cancers. The platform consists of three phenotype assays that recapitulate dormancy, migration, and single cell clonogenicity of tumor stem cells. These stem cells make up the hallmark characteristics of aggressive and highly invasive cancers responsible for recurrence and mortality. Each assay is designed to collect high content and high throughput data necessary for drug discovery and disease analysis. The platform can be used for screening drug libraries and identifying druggable targets for killing or disrupting dormant and migrating cells to expedite and de-risk the drug development process.
NEWS
11/15/2023
SingleCell Biotechnology awarded CPRIT Grant to optimize and advance its assays for use in drug development against Glioblastoma (GBM) brain tumors.
08/20/2023
SingleCell Biotechnology successfully tests platform with primary patient agnostic GBM samples.
01/25/2023
SingleCell Biotechnology successfully tests platform devices with GBM and Breast Cancer patient derived cell lines.
CONTACT US
Our Address
3060 Pegasus Park Dr., Dallas, TX 75247
The Biotech Hub of Dallas
Pegasus Park - Biotech Hub